Examines costs associated with disease progression and treatment in advanced endometrial cancer, suggesting improved upfront treatments could reduce this burden.
Patients with advanced EC initiating subsequent treatment face considerable HCRU and costs. Because most patients had a <6-month TFI, which is indicative of faster disease progression and associated with numerically higher HCRU and significantly higher EC-specific costs, this study suggests that effective up-front treatments may help alleviate this burden.
No takes yet. Share an insight, caveat, or question.
Moore-Schiltz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: